Mesoblast Limited
MESO · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 191.4% | -21.3% | -26.5% | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | 70.2% | -595.9% | -632.2% | -522.6% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -428.3% | -950.1% | -780.6% | -749.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -593.9% | -1,490.3% | -1,091.7% | -894.6% |
| EPS Diluted | -0.84 | -0.89 | -0.98 | -1.3 |
| % Growth | 5.6% | 9.2% | 24.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |